Intra-operative radiation therapy in pediatric neuroblastoma

P. J. Leavey, L. F. Odom, M. Poole, L. McNeely, R. W. Tyson, G. M. Haase

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

External beam irradiation (EBRT) has been shown to improve response rates and event-free survival in children with neuroblastoma and regional lymph node metastases. Irradiation during surgical exposure (intra-operative radiotherapy, IORT) with displacement of adjacent radiosensitive organ out of the treatment field allows for more precise delineation of the target volume and significantly reduces the amount of normal tissue exposed to irradiation. We have incorporated IORT into the treatment regimen of 24 children with neuroblastoma between the years 1983-1991. IORT was directed to any residual tumor or the tumor cell bed; the median dose of radiation was 1,000 cGY, equivalent to 3,000 cGY of conventional EBRT). There were 11 males and 13 females. Two patients had stage II, 12 patients had stage III, and 10 patients had stage IV disease. Ten children received IORT for suspected recurrent or persistent neuroblastoma. Twelve patients were disease-free survivors following IORT with a median follow-up of 54 months. For those patients with stage III disease, seven children were disease-free survivors, while only three of 10 patients with stage IV disease survived (median follow-up 30 months). Disease-free Survival (DFS) correlated with the achievement of local tumor control in children with both stage III and IV neuroblastoma. There was limited morbidity and no episodes of obstructive uropathy were encountered. We conclude that IORT appears to be well tolerated and may have therapeutic benefit for a select group of patients with neuroblastoma. IORT merits future exploration by prospective study.

Original languageEnglish (US)
Pages (from-to)424-428
Number of pages5
JournalMedical and Pediatric Oncology
Volume28
Issue number6
DOIs
StatePublished - 1997

Fingerprint

Neuroblastoma
Radiotherapy
Pediatrics
Disease-Free Survival
Survivors
Residual Neoplasm
Neoplasms
Therapeutics
Lymph Nodes
Prospective Studies
Radiation
Neoplasm Metastasis
Morbidity

Keywords

  • child
  • intra-operative radiotherapy
  • neuroblastoma
  • radiotherapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Intra-operative radiation therapy in pediatric neuroblastoma. / Leavey, P. J.; Odom, L. F.; Poole, M.; McNeely, L.; Tyson, R. W.; Haase, G. M.

In: Medical and Pediatric Oncology, Vol. 28, No. 6, 1997, p. 424-428.

Research output: Contribution to journalArticle

Leavey, P. J. ; Odom, L. F. ; Poole, M. ; McNeely, L. ; Tyson, R. W. ; Haase, G. M. / Intra-operative radiation therapy in pediatric neuroblastoma. In: Medical and Pediatric Oncology. 1997 ; Vol. 28, No. 6. pp. 424-428.
@article{80026975c0ed4801b1c0c18d84dd8fcd,
title = "Intra-operative radiation therapy in pediatric neuroblastoma",
abstract = "External beam irradiation (EBRT) has been shown to improve response rates and event-free survival in children with neuroblastoma and regional lymph node metastases. Irradiation during surgical exposure (intra-operative radiotherapy, IORT) with displacement of adjacent radiosensitive organ out of the treatment field allows for more precise delineation of the target volume and significantly reduces the amount of normal tissue exposed to irradiation. We have incorporated IORT into the treatment regimen of 24 children with neuroblastoma between the years 1983-1991. IORT was directed to any residual tumor or the tumor cell bed; the median dose of radiation was 1,000 cGY, equivalent to 3,000 cGY of conventional EBRT). There were 11 males and 13 females. Two patients had stage II, 12 patients had stage III, and 10 patients had stage IV disease. Ten children received IORT for suspected recurrent or persistent neuroblastoma. Twelve patients were disease-free survivors following IORT with a median follow-up of 54 months. For those patients with stage III disease, seven children were disease-free survivors, while only three of 10 patients with stage IV disease survived (median follow-up 30 months). Disease-free Survival (DFS) correlated with the achievement of local tumor control in children with both stage III and IV neuroblastoma. There was limited morbidity and no episodes of obstructive uropathy were encountered. We conclude that IORT appears to be well tolerated and may have therapeutic benefit for a select group of patients with neuroblastoma. IORT merits future exploration by prospective study.",
keywords = "child, intra-operative radiotherapy, neuroblastoma, radiotherapy",
author = "Leavey, {P. J.} and Odom, {L. F.} and M. Poole and L. McNeely and Tyson, {R. W.} and Haase, {G. M.}",
year = "1997",
doi = "10.1002/(SICI)1096-911X(199706)28:6<424::AID-MPO6>3.0.CO;2-I",
language = "English (US)",
volume = "28",
pages = "424--428",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Intra-operative radiation therapy in pediatric neuroblastoma

AU - Leavey, P. J.

AU - Odom, L. F.

AU - Poole, M.

AU - McNeely, L.

AU - Tyson, R. W.

AU - Haase, G. M.

PY - 1997

Y1 - 1997

N2 - External beam irradiation (EBRT) has been shown to improve response rates and event-free survival in children with neuroblastoma and regional lymph node metastases. Irradiation during surgical exposure (intra-operative radiotherapy, IORT) with displacement of adjacent radiosensitive organ out of the treatment field allows for more precise delineation of the target volume and significantly reduces the amount of normal tissue exposed to irradiation. We have incorporated IORT into the treatment regimen of 24 children with neuroblastoma between the years 1983-1991. IORT was directed to any residual tumor or the tumor cell bed; the median dose of radiation was 1,000 cGY, equivalent to 3,000 cGY of conventional EBRT). There were 11 males and 13 females. Two patients had stage II, 12 patients had stage III, and 10 patients had stage IV disease. Ten children received IORT for suspected recurrent or persistent neuroblastoma. Twelve patients were disease-free survivors following IORT with a median follow-up of 54 months. For those patients with stage III disease, seven children were disease-free survivors, while only three of 10 patients with stage IV disease survived (median follow-up 30 months). Disease-free Survival (DFS) correlated with the achievement of local tumor control in children with both stage III and IV neuroblastoma. There was limited morbidity and no episodes of obstructive uropathy were encountered. We conclude that IORT appears to be well tolerated and may have therapeutic benefit for a select group of patients with neuroblastoma. IORT merits future exploration by prospective study.

AB - External beam irradiation (EBRT) has been shown to improve response rates and event-free survival in children with neuroblastoma and regional lymph node metastases. Irradiation during surgical exposure (intra-operative radiotherapy, IORT) with displacement of adjacent radiosensitive organ out of the treatment field allows for more precise delineation of the target volume and significantly reduces the amount of normal tissue exposed to irradiation. We have incorporated IORT into the treatment regimen of 24 children with neuroblastoma between the years 1983-1991. IORT was directed to any residual tumor or the tumor cell bed; the median dose of radiation was 1,000 cGY, equivalent to 3,000 cGY of conventional EBRT). There were 11 males and 13 females. Two patients had stage II, 12 patients had stage III, and 10 patients had stage IV disease. Ten children received IORT for suspected recurrent or persistent neuroblastoma. Twelve patients were disease-free survivors following IORT with a median follow-up of 54 months. For those patients with stage III disease, seven children were disease-free survivors, while only three of 10 patients with stage IV disease survived (median follow-up 30 months). Disease-free Survival (DFS) correlated with the achievement of local tumor control in children with both stage III and IV neuroblastoma. There was limited morbidity and no episodes of obstructive uropathy were encountered. We conclude that IORT appears to be well tolerated and may have therapeutic benefit for a select group of patients with neuroblastoma. IORT merits future exploration by prospective study.

KW - child

KW - intra-operative radiotherapy

KW - neuroblastoma

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0030928947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030928947&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-911X(199706)28:6<424::AID-MPO6>3.0.CO;2-I

DO - 10.1002/(SICI)1096-911X(199706)28:6<424::AID-MPO6>3.0.CO;2-I

M3 - Article

C2 - 9143387

AN - SCOPUS:0030928947

VL - 28

SP - 424

EP - 428

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -